NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 305 filers reported holding NOVOCURE LTD in Q3 2022. The put-call ratio across all filers is 1.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $463,973 | -56.8% | 28,729 | +10.9% | 0.00% | -55.6% |
| Q2 2023 | $1,074,933 | -34.9% | 25,902 | -5.7% | 0.01% | -40.0% |
| Q1 2023 | $1,651,444 | -15.6% | 27,460 | +2.9% | 0.02% | -21.1% |
| Q4 2022 | $1,957,125 | -0.4% | 26,682 | +3.2% | 0.02% | -5.0% |
| Q3 2022 | $1,964,000 | +7.7% | 25,844 | -1.5% | 0.02% | +11.1% |
| Q2 2022 | $1,823,000 | -15.4% | 26,228 | +0.8% | 0.02% | +5.9% |
| Q1 2022 | $2,155,000 | +13.0% | 26,009 | +2.4% | 0.02% | +13.3% |
| Q4 2021 | $1,907,000 | -37.1% | 25,398 | -2.8% | 0.02% | -40.0% |
| Q3 2021 | $3,034,000 | -47.5% | 26,119 | +0.3% | 0.02% | -46.8% |
| Q2 2021 | $5,779,000 | +75.2% | 26,052 | +4.4% | 0.05% | +62.1% |
| Q1 2021 | $3,298,000 | -22.7% | 24,948 | +1.2% | 0.03% | -25.6% |
| Q4 2020 | $4,264,000 | +48.7% | 24,640 | -4.3% | 0.04% | +34.5% |
| Q3 2020 | $2,867,000 | +152.8% | 25,760 | +34.8% | 0.03% | +81.2% |
| Q2 2020 | $1,134,000 | -9.4% | 19,116 | +2.8% | 0.02% | -27.3% |
| Q1 2020 | $1,252,000 | – | 18,587 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $29,071,000 | 12.94% |
| HARTLINE INVESTMENT CORP/ | 302,194 | $67,033,000 | 8.47% |
| Deep Track Capital, LP | 1,000,000 | $82,850,000 | 5.31% |
| MORGAN JESS S & CO INC | 48,860 | $4,048,000 | 2.94% |
| Taylor Frigon Capital Management LLC | 73,014 | $6,049,000 | 2.24% |
| Private Harbour Investment Management & Counsel, LLC | 13,263 | $1,099,000 | 0.92% |
| HighVista Strategies LLC | 17,448 | $1,446,000 | 0.92% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $829,000 | 0.79% |
| Lloyd Park, LLC | 6,700 | $555,000 | 0.61% |
| Rhenman & Partners Asset Management AB | 69,700 | $5,775,000 | 0.57% |